Literature DB >> 11168078

Chlamydia trachomatis and human papillomavirus infection in Indian women with sexually transmitted diseases and cervical precancerous and cancerous lesions.

V Gopalkrishna1, N Aggarwal, V L Malhotra, R V Koranne, V P Mohan, A Mittal, B C Das.   

Abstract

OBJECTIVES: Sexually transmitted diseases (STDs) and anogenital cancers are the major health problems in Indian women but no reliable estimate of the prevalence of either genital chlamydial infection or human papillomavirus (HPV) infection in STD patients is available. The aim of this study was to detect the frequency of Chlamydia trachomatis and the most prevalent high-risk HPV type 16 (HPV 16) infection in Indian women, with STDs and precancerous and cancerous lesions of the uterine cervix by polymerase chain reaction (PCR), and their comparison with those of conventional serology and antigen tests used for C. trachomatis detection.
METHODS: Endocervical swabs or scrapes were collected from 50 women with STDs and 30 normal healthy women attending the STD clinics of Smt. Sucheta Kripalani Hospital, New Delhi. Scraped cervical cell specimens were also collected from 50 women with precancerous and cancerous lesions of the uterine cervix. Detection of C. trachomatis and HPV was carried out by PCR using chlamydia and HPV genome-specific oligonucleotide primers. The detection of chlamydial antigen and IgG-specific antibodies was carried out by enzyme immunoassay (EIA) and serological enzyme-linked immunosorbent assay (ELISA), respectively.
RESULTS: A chlamydia plasmid-based PCR assay detected 50% (25 of 50) positivity of C. trachomatis in STD patients and HPV 16 DNA was found in 30% (15 of 50) of these cases which are significantly higher than those found in healthy controls. The PCR estimate of chlamydia was found to be higher than its reported frequency by tissue culture. The EIA could detect chlamydial antigen in only 13 cases (26%) while serological ELISA revealed evidence of chlamydia IgG-specific antibodies in 26 (52%) cases. Interestingly, in women with precancerous and cancerous lesions, the rate of HPV 16 infection was very high (52% and 72%, respectively), whereas the frequency of chlamydia infection was found to be 12-22% only. Occurrence of other sexually transmitted agents was also evaluated in the women.
CONCLUSIONS: This is the first PCR estimate of genital chlamydial (50%) and HPV 16 (30%) infection in STD patients and women with precancerous and cancerous lesions of the uterine cervix in India. The PCR method seems to be a good alternative to tissue culture.

Entities:  

Mesh:

Year:  2000        PMID: 11168078     DOI: 10.1046/j.1469-0691.2000.00024.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  13 in total

1.  Utility of pooled urine specimens for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in men attending public sexually transmitted infection clinics in Mumbai, India, by PCR.

Authors:  Christina Lindan; Meenakshi Mathur; Sameer Kumta; Hermangi Jerajani; Alka Gogate; Julius Schachter; Jeanne Moncada
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

2.  Chlamydia trachomatis infection and human papillomavirus in women with cervical neoplasia in Pernambuco-Brazil.

Authors:  Mayara Costa Mansur Tavares; Jamilly Lopes de Macêdo; Sérgio Ferreira de Lima Júnior; Sandra de Andrade Heráclio; Melânia Maria Ramos Amorim; Maria de Mascena Diniz Maia; Paulo Roberto Eleutério de Souza
Journal:  Mol Biol Rep       Date:  2014-01-07       Impact factor: 2.316

3.  Serovar-specific immune responses to peptides of variable regions of Chlamydia trachomatis major outer membrane protein in serovar D-infected women.

Authors:  Pragya Srivastava; Rishein Gupta; Hem Chandra Jha; Rajneesh Jha; Apurb Rashmi Bhengraj; Sudha Salhan; Aruna Mittal
Journal:  Clin Exp Med       Date:  2008-09-25       Impact factor: 3.984

4.  Mucosal and peripheral immune responses to chlamydial heat shock proteins in women infected with Chlamydia trachomatis.

Authors:  T Agrawal; V Vats; S Salhan; A Mittal
Journal:  Clin Exp Immunol       Date:  2007-06       Impact factor: 4.330

5.  Novel missense mutation in FHIT gene: interpreting the effect in HPV-mediated cervical cancer in Indian women.

Authors:  Md Kausar Neyaz; Showket Hussain; Md Imtaiyaz Hassan; Bhudev C Das; Syed Akhtar Husain; Mausumi Bharadwaj
Journal:  Mol Cell Biochem       Date:  2010-02       Impact factor: 3.396

6.  Molecular detection of HPV and Chlamydia trachomatis infections in Brazilian women with abnormal cervical cytology.

Authors:  André L P de Abreu; Paula R B Nogara; Raquel P Souza; Mariana C da Silva; Nelson S Uchimura; Rodrigo L Zanko; Erika C Ferreira; Maria C B Tognim; Jorge J V Teixeira; Fabrícia Gimenes; Marcia E L Consolaro
Journal:  Am J Trop Med Hyg       Date:  2012-11-05       Impact factor: 2.345

Review 7.  Association of Genital Infections Other Than Human Papillomavirus with Pre-Invasive and Invasive Cervical Neoplasia.

Authors:  Ishita Ghosh; Ranajit Mandal; Pratip Kundu; Jaydip Biswas
Journal:  J Clin Diagn Res       Date:  2016-02-01

Review 8.  Burden of Chlamydia trachomatis in India: a systematic literature review.

Authors:  Pierre Thomas; Joke Spaargaren; Rajiv Kant; Rubina Lawrence; Arvind Dayal; Jonathan A Lal; Servaas A Morré
Journal:  Pathog Dis       Date:  2017-07-31       Impact factor: 3.166

9.  Association of Chlamydia trachomatis infection with human papillomavirus (HPV) & cervical intraepithelial neoplasia - a pilot study.

Authors:  Neerja Bhatla; Kriti Puri; Elizabeth Joseph; Alka Kriplani; Venkateswaran K Iyer; V Sreenivas
Journal:  Indian J Med Res       Date:  2013-03       Impact factor: 2.375

10.  Genotyping of Endocervical Chlamydia trachomatis Strains and Detection of Serological Markers of Acute and Chronic Inflammation in Their Host.

Authors:  Behrouz Taheri Beni; Anahita Jenab; Rasoul Roghanian; Hossein Motamedi; Naser Golbang; Pouran Golbang; Javad Zaeimi Yazdi
Journal:  Int J Fertil Steril       Date:  2012-06-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.